Macomics Signs a Worldwide Drug Discovery Collaboration Agreement with Ono to Discover and Develop Macrophage-Targeting Antibody Therapy for Cancer
- Macomics to receive an up front & R&D funding, and is also eligible to receive success-based milestones along with royalties based on global net sales. Ono gets an exclusive option to license rights globally to the candidates for further development and commercialization
- Macomics will use its ENIGMACT macrophage drug discovery platform for the identification and characterization of new immuno-oncology antibody drugs against the novel target of interest
- To find new targets and reveal disease-specific target biology, Macomics' ENIGMAC macrophage drug discovery platform combines high-volume human data sets, personalized cell models, and human macrophage genome editing technology
Ref: Ono Pharmaceutical | Image: Ono Pharmaceutical
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.